Danish Pharmacovigilance Update 28 November 2013

In this issue of Danish Pharmacovigilance Update:

News from the EU

• Acipimox (Olbetam®) should only be used to lower triglycerides when other treatments of dyslipidaemia are not sufficient
• Risk of blood clots from the use of the cancer medicine ponatinib (Iclusig®)
• All patients should be screened for hepatitis B virus (HBV) before starting treatment with rituximab (Mabthera®)
• Preparation error resulting in overdose of cabazitaxel (Jevtana)

News from the Danish Health and Medicines Authority

• Ciprofloxacin and the risk of tendon disorders
• Decrease in the use of medicines for the treatment of anogenital warts in adolescents under the age of 20
• Bisphosphonates/denosumab and the risk of osteonecrosis of the jaw
• The tugboats of preventive health – an article from the Danish weekly newspaper Weekendavisen

Short news

• Batches of the NovoMix®30 FlexPen® recalled
• Reporting of adverse reactions to the Danish Health and Medicines Authority
• Danish Pharmacovigilance Update celebrates its 4th anniversary